TG Therapeutics Sees 92% YoY BRIUMVI Growth, 2026 Revenue Target $875–$900M
TG Therapeutics reported Q4 2025 revenue of $192.6 million and full-year 2025 revenue of $616.3 million, driven by BRIUMVI U.S. net sales of $182.7 million (+20% sequential) and $594.1 million (+92% year-over-year). The company forecasts fiscal 2026 global revenue of $875–$900 million, including U.S. BRIUMVI sales of $825–$850 million.
1. Q4 and Full-Year 2025 Revenue
TG Therapeutics posted total revenues of $192.6 million in Q4 2025 and $616.3 million for the full year. U.S. net sales of BRIUMVI reached $182.7 million in Q4 (+20% sequential) and $594.1 million full-year (+92% year-over-year), making it the primary revenue driver.
2. International Commercialization Expansion
The company expanded BRIUMVI commercialization outside the U.S. through partner Neuraxpharm. Approvals have been secured in the European Union, United Kingdom, Switzerland, Australia, Kuwait and the United Arab Emirates.
3. 2026 Revenue Outlook
Management targets global revenue of $875–$900 million for fiscal 2026, underpinned by projected U.S. BRIUMVI net sales of $825–$850 million. This guidance reflects expectations for continued product adoption and new market launches.
4. Pipeline and Product Portfolio
TG Therapeutics’ product portfolio includes TG-1501, TG-1701, Ublituximab and Umbralisib, targeting B-cell malignancies and autoimmune diseases. These clinical-stage assets support long-term growth beyond current BRIUMVI revenues.